STOCK TITAN
  1. Home
  2. Sec-filings
  3. CTNM
  4. [Form 4] Contineum Therapeutics, Inc. Insider Trading Activity

Contineum Therapeutics (CTNM) grants director 19,000 stock options at $14.19

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Contineum Therapeutics director Evert B. Schimmelpennink received a routine equity grant. He was granted stock options for 19,000 shares of Class A Common Stock at an exercise price of $14.19 per share under the 2024 Equity Incentive Plan. These options vest in full on the earlier of June 26, 2027 or the next regular annual stockholder meeting and expire on June 25, 2036. This is a compensation-related award, not an open-market purchase or sale.

Positive

  • None.

Negative

  • None.
Insider Schimmelpennink Evert B.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 19,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 19,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 19,000 shares Stock Option (right to buy) for Class A Common Stock
Exercise price $14.19 per share Conversion or exercise price of stock options
Expiration date June 25, 2036 Option expiration for director grant
Shares underlying options 19,000 shares Underlying Class A Common Stock covered by the options
Holdings after grant (options) 19,000 derivative shares Total stock options following the transaction
Vesting date trigger June 26, 2027 or next annual meeting Options vest on earlier of these dates, subject to service
2024 Equity Incentive Plan financial
"Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"),"
Non-Employee Director Compensation Program financial
"pursuant to the Issuer's Non-Employee Director Compensation Program, as amended,"
stock option financial
"will automatically be granted a stock option under the Plan for 19,000 shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Class A Common Stock financial
"a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock."
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schimmelpennink Evert B.
(Last)(First)(Middle)
3565 GENERAL ATOMICS COURT, SUITE 200
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$14.1906/26/2026A19,000 (1)06/25/2036Class A Common Stock19,000$019,000D
Explanation of Responses:
1. Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 19,000 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2027, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.
Remarks:
/s/ Peter Slover, Attorney-in-Fact06/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Contineum Therapeutics (CTNM) disclose in this Form 4 filing?

Contineum Therapeutics reported a grant of stock options to director Evert B. Schimmelpennink. He received options for 19,000 Class A Common shares as part of the company’s 2024 Equity Incentive Plan and non-employee director compensation program.

How many CTNM shares are covered by the new option grant to Evert B. Schimmelpennink?

The option grant covers 19,000 shares of Contineum Therapeutics Class A Common Stock. These options represent a compensation award for serving as a non-employee director, rather than a direct market purchase or sale of existing CTNM shares.

What is the exercise price and term of the new Contineum Therapeutics options?

The granted stock options have an exercise price of $14.19 per share and expire on June 25, 2036. This means the director can purchase 19,000 shares at $14.19 any time before the expiration date, once the options are vested.

When do Evert B. Schimmelpennink’s CTNM stock options vest?

The options vest in full on the earlier of June 26, 2027 or Contineum Therapeutics’ next regular annual stockholder meeting. Vesting is contingent on the director’s continuous service on the company’s Board of Directors through the applicable vesting date.

Is this CTNM Form 4 transaction a stock purchase or sale on the market?

No, this Form 4 reflects a grant of stock options as compensation, not an open-market trade. The director did not buy or sell CTNM shares; instead, he received the right to purchase 19,000 shares later at a fixed exercise price.

Under which plan were the Contineum Therapeutics options granted to the director?

The options were granted under Contineum Therapeutics’ 2024 Equity Incentive Plan, pursuant to its Non-Employee Director Compensation Program. That program automatically grants 19,000-share stock options to each continuing non-employee director after each regular annual stockholder meeting.